Industry
Biotechnology
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Loading...
Open
13.48
Mkt cap
1.2B
Volume
3.3M
High
14.12
P/E Ratio
-3.83
52-wk high
25.34
Low
13.26
Div yield
N/A
52-wk low
13.26
Portfolio Pulse from
November 15, 2024 | 11:45 pm
Portfolio Pulse from
November 12, 2024 | 12:15 pm
Portfolio Pulse from
November 06, 2024 | 2:00 am
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 1:45 pm
Portfolio Pulse from Avi Kapoor
October 24, 2024 | 11:40 am
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 11:22 am
Portfolio Pulse from Benzinga Newsdesk
October 14, 2024 | 1:25 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.